SNGX.US Soligenix Inc.

Healthcare Biotechnology USA Stocks
0.2805 USD
Close of Nov 18, 2026
0.2662 1.70
Market cap
USD 6.55M
P/E
-
P/B
1.08x
ROE
-126.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SNGX.US undervalued?

Graham number

The Graham number of Soligenix Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Soligenix Inc. fundamental analysis

No fundamental analysis for Soligenix Inc. yet.

Soligenix Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Soligenix Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulato…

Full company profile